MT-CYB Antibody
Description
Definition and Target Profile
MT-CYB (mitochondrially encoded cytochrome b) is a 380-amino acid protein encoded by the mitochondrial MT-CYB gene. It is a critical component of the ubiquinol-cytochrome c reductase complex (Complex III), which facilitates electron transfer in the mitochondrial respiratory chain and contributes to ATP synthesis .
MT-CYB Antibodies are polyclonal or monoclonal reagents validated for applications such as:
-
Western Blot (WB)
-
Immunohistochemistry (IHC)
-
ELISA
These antibodies are essential for detecting MT-CYB in tissues like muscle, liver, and brain, where mitochondrial activity is high .
Protein Characteristics
MT-CYB’s hydrophobic structure enables integration into mitochondrial membranes, where it stabilizes Complex III and supports oxidative phosphorylation .
Clinical and Research Significance
MT-CYB mutations are linked to mitochondrial disorders and other diseases:
Key Research Findings
Supplier Comparison
| Supplier | Catalog Number | Host | Applications | Reactivity |
|---|---|---|---|---|
| Proteintech | 55090-1-AP | Rabbit | WB, ELISA | Human, Mouse |
| Abcam | ab198860 | Rabbit | IHC-P | Human |
| Boster Bio | A03737 | Rabbit | WB, ELISA | Human, Mouse |
| Thermo Fisher | PA5-100740 | Rabbit | IF, WB | Human, Mouse, Rat |
Notes:
-
Immunogens often include synthesized peptides (e.g., residues 331–380 for Boster Bio’s A03737) .
-
Antibodies are typically validated using knockout/knockdown controls and tissue-specific lysates .
Protocol Recommendations
-
Western Blot: Use 1:500–1:2000 dilutions with mitochondrial-enriched lysates .
-
Immunohistochemistry: Optimize antigen retrieval using citrate buffer (pH 6.0) for formalin-fixed tissues .
Emerging Research Directions
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
Q&A
Basic Research Questions
How to validate MT-CYB antibody specificity in mitochondrial studies?
-
Methodological steps:
-
Perform Western blot with positive controls (e.g., tissues with confirmed MT-CYB expression like skeletal muscle) and negative controls (e.g., MT-CYB knockout models or ρ⁰ cells lacking mitochondrial DNA) .
-
Use subcellular fractionation to confirm mitochondrial localization, followed by protease protection assays to verify membrane topology .
-
Validate via siRNA knockdown in cell lines to observe reduced signal intensity .
-
Cross-reference with NGS data to correlate protein expression levels with mtDNA heteroplasmy ratios .
-
What experimental controls are critical for immunohistochemical (IHC) detection of MT-CYB?
-
Essential controls:
How to select MT-CYB antibodies for dual detection in multi-species studies?
-
Approach:
Advanced Research Questions
How to resolve discrepancies in MT-CYB expression data across mitochondrial disease models?
-
Key considerations:
-
Heteroplasmy levels: Quantify mtDNA deletion/point mutation loads via qPCR or NGS, as MT-CYB protein levels may not correlate linearly with mutation burden .
-
Tissue specificity: Muscle biopsies show higher sensitivity than blood for detecting MT-CYB defects .
-
Technical variability: Standardize mitochondrial isolation protocols to avoid contamination from nuclear-encoded paralogs .
-
What methods optimize MT-CYB detection in tissues with complex III assembly defects?
-
Strategies:
How to correlate MT-CYB antibody signals with functional respiratory chain deficits?
-
Integrated workflow:
Data Contradiction Analysis
Key Research Findings
-
MT-CYB in severe COVID-19: Elevated plasma MT-CYB levels correlate with ICU admission (AUC = 0.82) and intubation risk (AUC = 0.79), outperforming CRP and ferritin .
-
Mutation hotspots: The 21-bp deletion (p.His215_Phe221del) disrupts β-strand structure, causing complex III instability .
-
Cross-species conservation: Zebrafish MT-CYB shares 78% amino acid identity with human homolog, enabling comparative studies .
